Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.

Michael Roost Clausen; Pieternella Lugtenburg; Martin Hutchings; Peter W. M. Johnson; Kim M. Linton; David John Lewis; Martine Chamuleau; Anna Sureda Balari; David Cunningham; Brian Elliott; Dena DeMarco; Kuo-mei Chen; Rogier Mous

doi:10.1200/JCO.2021.39.15_suppl.7518

Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.

Michael Roost Clausen, Pieternella Lugtenburg, Martin Hutchings, Peter W. M. Johnson, Kim M. Linton, David John Lewis, Martine Chamuleau, Anna Sureda Balari, David Cunningham, Brian Elliott, Dena DeMarco, Kuo-mei Chen, Rogier Mous

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	39
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.7518
Publication status	Published - 20 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2021.39.15_suppl.7518

Cite this

Clausen, M. R., Lugtenburg, P., Hutchings, M., Johnson, P. W. M., Linton, K. M., Lewis, D. J., Chamuleau, M., Balari, A. S., Cunningham, D., Elliott, B., DeMarco, D., Chen, K., & Mous, R. (2021). Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. Journal of Clinical Oncology, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.7518

@article{d66fc44c02c146f7b38a429f94ca7aae,

title = "Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.",

author = "Clausen, {Michael Roost} and Pieternella Lugtenburg and Martin Hutchings and Johnson, {Peter W. M.} and Linton, {Kim M.} and Lewis, {David John} and Martine Chamuleau and Balari, {Anna Sureda} and David Cunningham and Brian Elliott and Dena DeMarco and Kuo-mei Chen and Rogier Mous",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15_suppl.7518",

language = "English",

volume = "39",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15",

}

Clausen, MR, Lugtenburg, P, Hutchings, M, Johnson, PWM, Linton, KM, Lewis, DJ, Chamuleau, M, Balari, AS, Cunningham, D, Elliott, B, DeMarco, D, Chen, K & Mous, R 2021, 'Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.', Journal of Clinical Oncology, vol. 39, no. 15. https://doi.org/10.1200/JCO.2021.39.15_suppl.7518

TY - JOUR

T1 - Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

T2 - Safety profile and antitumor activity.

AU - Clausen, Michael Roost

AU - Lugtenburg, Pieternella

AU - Hutchings, Martin

AU - Johnson, Peter W. M.

AU - Linton, Kim M.

AU - Lewis, David John

AU - Chamuleau, Martine

AU - Balari, Anna Sureda

AU - Cunningham, David

AU - Elliott, Brian

AU - DeMarco, Dena

AU - Chen, Kuo-mei

AU - Mous, Rogier

PY - 2021/5/20

Y1 - 2021/5/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000708120604115&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1200/JCO.2021.39.15_suppl.7518

DO - 10.1200/JCO.2021.39.15_suppl.7518

M3 - Meeting Abstract

SN - 0732-183X

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.

UN SDGs

Access to Document

Other files and links

Cite this